Merck & Co., Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a leading research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products worldwide; key human health offerings include oncology drugs such as Keytruda (pembrolizumab), the PD-1 inhibitor generating $29.5 billion in 2024 revenues for various cancers, Lynparza (olaparib), a PARP inhibitor for BRCA-mutated ovarian cancer, vaccines like Gardasil (HPV vaccine, $8.6 billion in 2024 revenues), ProQuad/M-M-R II/Varivax (MMRV combination vaccine, $2.5 billion in 2024 revenues), and additional products including Cancidas (caspofungin acetate) antifungal, Januvia/Janumet for diabetes, and veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Headquartered in Rahway, New Jersey, and founded over 130 years ago, the company operates globally across human health and animal health segments, targeting patients, healthcare providers, and animal health customers in major markets including the United States, Europe, Asia, and emerging regions. Recent developments include a November 2025 research and development funding agreement with Blackstone Life Sciences for $700 million to advance sacituzumab tirumotecan (sac-TMT), an investigational TROP2-targeted antibody-drug conjugate in 15 Phase 3 trials for breast, endometrial, and lung cancers; multiyear manufacturing expansions totaling nearly $6 billion across North Carolina, Delaware, Kansas, and Virginia to boost vaccine, biologic, and Keytruda production capacity as part of a broader $70 billion U.S. investment commitment; and a launched $3 billion restructuring plan emphasizing productivity savings and U.S.-based R&D and manufacturing enhancements.
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?
Dimensional Fund Advisors LP Acquires 2,969,856 Shares of Merck & Co., Inc. $MRK
What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.
Merck & Co., Inc. $MRK Shares Sold by AIA Group Ltd
Allspring Global Investments Holdings LLC Has $81.27 Million Stake in Merck & Co., Inc. $MRK
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy
Use These ETFs as Health Stocks LLY, UNH, MRK Thrive
New Cholesterol Pill, Earnings Growth Boost Merck Shares
FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio
FDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kind
Nasdaq slides as chip selloff drags Wall Street lower
Nasdaq dragged by chip sell-off, Abbott, UnitedHealth lead risers
Merck's cholesterol pill gets US FDA approval
Merck Gets Approval for Powerful Cholesterol-Cutting Pill
The FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve
Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer